Vigabatrin (Epilepsy)

Table   Graphic  
individual studies
OutcomeTE95% CIn casesn exposedkPub. bias Congenital malformations All congenital malformations (majors, minors, majors and minors, or unspecified) Morrow (Vigabatrin) (Controls unexposed, sick), 2006 Mawer (Vigabatrin) (Controls unexposed, sick), 2010 Tomson (Vigabatrin), 2018 Vajda (Vigabatrin) (Controls unexposed, sick), 2019 46.93[1.26; 38.13]8812not evaluable Major congenital malformations Morrow (Vigabatrin) (Controls unexposed, sick), 2006 Mawer (Vigabatrin) (Controls unexposed, sick), 2010 Tomson (Vigabatrin), 2018 Vajda (Vigabatrin) (Controls unexposed, sick), 2019 46.93[1.26; 38.13]8812not evaluable Congenital heart defects Morrow (Vigabatrin) (Controls exposed to Lamotrigine, sick), 2006 112.98[0.62; 271.33]46not evaluable Digestive system anomalies Morrow (Vigabatrin) (Controls exposed to Lamotrigine, sick), 2006 116.71[0.77; 363.61]36not evaluable Hypospadias Morrow (Vigabatrin) (Controls exposed to Lamotrigine, sick), 2006 18.96[0.45; 179.29]66not evaluable Limb defects Morrow (Vigabatrin) (Controls exposed to Lamotrigine, sick), 2006 123.44[1.00; 547.07]26not evaluable Neural Tube Defects Morrow (Vigabatrin) (Controls exposed to Lamotrigine, sick), 2006 139.12[1.43; 1070.14]16not evaluable Oro-facial clefts Morrow (Vigabatrin) (Controls exposed to Lamotrigine, sick), 2006 139.12[1.43; 1070.14]16not evaluable0.2100.01.0

- About - Master protocol - Browse exposition - RSS - Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons